CXCL12 promoter methylation significantly distinguished cancer from benign and normal prostate tissues in an FFPE cohort (PCa n = 25; adjacent tissues n = 22, BPH n = 19; p < 0.05) [66]. The gene discussed is CXCL12; the disease is posterior cortical atrophy.